Latest Bioniche Life Scienc (BNHLF) Headlines
Bioniche Life Sciences Inc. Announces Key Corporate Updates
PR Newswire - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:56AM CST
Trading resumes in:
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
PR Newswire - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:11AM CST
The following issues have been halted by IIROC:
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer
PR Newswire - Tue Jan 07, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage biotechnology company, today announced the appointment of Donald Olds as Chief Operating Officer, effective immediately.
Bioniche Life Sciences Inc. Delisting Approved by the ASX
PR Newswire - Wed Dec 11, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC, ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announces that the Australian Securities Exchange (ASX) has approved the Company's application to delist from the official list of the ASX subject to certain usual conditions.
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada
PR Newswire - Wed Dec 04, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a study approved for publication in the Journal of Food Protection demonstrates that Verotoxigenic Escherichia coli (VTEC) results in a cost of $403.9 million per year in Canada related to primary infections and long-term health outcomes. More than 93% of the VTEC infections are caused by the O157 strain of E. coli, and Bioniche One Health has developed a cattle vaccine to reduce the burden of this pathogen.
Bioniche Life Sciences Inc. Horse Product Approved for Sale in the U.S.
PR Newswire - Sun Dec 01, 4:00PM CST
a purified hyaluronate sodium I.V./I.A. product for horses-
Bioniche Life Sciences Inc. Reports Fiscal 2014 First Quarter Results
PR Newswire - Tue Nov 05, 7:25PM CST
(all figures are in Canadian dollars unless otherwise noted)
Bioniche Life Sciences Inc. Announces the Appointment of a New Chief Executive Officer
PR Newswire - Mon Nov 04, 7:30AM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has hired Dr. Michael Berendt as its new CEO effective immediately. Dr. Berendt replaces Mr. Graeme McRae in this role. Earlier this year, Mr. McRae announced his intention to retire and assume the role of Founder and Chairman Emeritus of the Company's Board of Directors.
Bioniche Management Proxy Circular for 2013 Annual and Special Meeting Now Available
PR Newswire - Fri Oct 18, 4:00PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has posted on the Company's website (www.Bioniche.com), on SEDAR www.sedar.com, and on www.ASX.com.au the management proxy circular relating to the Annual and Special Meeting of Bioniche Life Sciences Inc. Shareholders. The notice of meeting and management information circular (the "Circular") has been mailed to all shareholders of record as at September 9, 2013.
Bioniche Provides an Update on Plans for a New Drug Submission Filing in Canada
PR Newswire - Mon Oct 07, 4:00PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its plans for a New Drug Submission filing in Canada for Urocidin™, the Company's Phase III bladder cancer product.
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement
PR Newswire - Wed Sep 11, 1:13PM CDT
new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders -
Bioniche Founder and CEO Announces his New Role with the Company
PR Newswire - Wed Sep 11, 11:03AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today issued an open letter to all shareholders from Founder, President & CEO, Graeme McRae, regarding his going forward role with the Company:
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bioniche Life Sciences Inc. Announces Key Corporate Updates
PR Newswire - Tue Mar 04, 8:00AM CST
Bioniche Life Sciences Inc. (TSX: BNC) announced today key corporate updates:
Vétoquinol to Acquire the Animal Health Business of Bioniche Life Sciences Inc.
PR Newswire - Thu Feb 27, 3:58PM CST
Vétoquinol (NYSE Euronext Paris: VETO) and Bioniche Life Sciences Inc. (TSX: BNC), today jointly announced their signing of a share purchase agreement under which Vétoquinol has agreed to purchase Bioniche's Animal Health business for the cash purchase price of CAD$61 million. This agreement remains subject to the approval by shareholders of Bioniche Life Sciences Inc., and the usual closing conditions for a transaction of this type. The Boards of Directors of both corporations have approved the binding agreement, and notice of a special Bioniche shareholder meeting will be forthcoming.
IIROC Trade Resumption - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:56AM CST
Trading resumes in:
Bioniche Life Sciences Inc. Reports Fiscal 2014 Second Quarter Results and Announces Strategic Expenditure Review and New One Health Strategy
PR Newswire - Thu Feb 06, 11:47AM CST
(all figures are in Canadian dollars unless otherwise noted)
IIROC Trade Halt - Bioniche Life Sciences Inc.
Newsfile Corp - Thu Feb 06, 11:11AM CST
The following issues have been halted by IIROC:
Bioniche Life Sciences Inc. Appoints a Chief Operating Officer
PR Newswire - Tue Jan 07, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a leading clinical stage biotechnology company, today announced the appointment of Donald Olds as Chief Operating Officer, effective immediately.
Bioniche Life Sciences Inc. Delisting Approved by the ASX
PR Newswire - Wed Dec 11, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC, ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announces that the Australian Securities Exchange (ASX) has approved the Company's application to delist from the official list of the ASX subject to certain usual conditions.
Primary and Long-Term Illness Related to E. coli O157 Costs $403.9 Million per Year in Canada
PR Newswire - Wed Dec 04, 4:00PM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that a study approved for publication in the Journal of Food Protection demonstrates that Verotoxigenic Escherichia coli (VTEC) results in a cost of $403.9 million per year in Canada related to primary infections and long-term health outcomes. More than 93% of the VTEC infections are caused by the O157 strain of E. coli, and Bioniche One Health has developed a cattle vaccine to reduce the burden of this pathogen.
Bioniche Life Sciences Inc. Horse Product Approved for Sale in the U.S.
PR Newswire - Sun Dec 01, 4:00PM CST
a purified hyaluronate sodium I.V./I.A. product for horses-
Bioniche Life Sciences Inc. Reports Fiscal 2014 First Quarter Results
PR Newswire - Tue Nov 05, 7:25PM CST
(all figures are in Canadian dollars unless otherwise noted)
Bioniche Life Sciences Inc. Announces the Appointment of a New Chief Executive Officer
PR Newswire - Mon Nov 04, 7:30AM CST
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has hired Dr. Michael Berendt as its new CEO effective immediately. Dr. Berendt replaces Mr. Graeme McRae in this role. Earlier this year, Mr. McRae announced his intention to retire and assume the role of Founder and Chairman Emeritus of the Company's Board of Directors.
Bioniche Management Proxy Circular for 2013 Annual and Special Meeting Now Available
PR Newswire - Fri Oct 18, 4:00PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has posted on the Company's website (www.Bioniche.com), on SEDAR www.sedar.com, and on www.ASX.com.au the management proxy circular relating to the Annual and Special Meeting of Bioniche Life Sciences Inc. Shareholders. The notice of meeting and management information circular (the "Circular") has been mailed to all shareholders of record as at September 9, 2013.
Bioniche Provides an Update on Plans for a New Drug Submission Filing in Canada
PR Newswire - Mon Oct 07, 4:00PM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its plans for a New Drug Submission filing in Canada for Urocidin™, the Company's Phase III bladder cancer product.
Bioniche Life Sciences Inc. and Concerned Shareholders Announce a Settlement
PR Newswire - Wed Sep 11, 1:13PM CDT
new Board to oversee sale of Animal Health and sale/partnering of VMC with commitment to return capital to shareholders -
Bioniche Founder and CEO Announces his New Role with the Company
PR Newswire - Wed Sep 11, 11:03AM CDT
Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today issued an open letter to all shareholders from Founder, President & CEO, Graeme McRae, regarding his going forward role with the Company:
Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
